Alnylam Commits Up to $2B to AI-Driven Therapeutic Innovation -- Company Talk

Dow Jones

Jun 04

Alnylam's new strategic partnership with Inceptive Nucleics carries a potential value of up to $2 billion, with an upfront payment of $30 million in cash and equity. The deal pairs Inceptive's generative artificial intelligence models with Alnylam's research engine as part of the company's Alnylam 2030 strategy. Alnylam CEO Yvonne Greenstreet said the collaboration aims to accelerate the creation of transformative medicines with speed and sophistication not previously possible. The structure includes additional milestone payments tied to preclinical, regulatory, and commercial achievements.

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.

(END) Dow Jones Newswires

June 03, 2026 17:28 ET (21:28 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2640182669"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640182669\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640182669?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 05:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640182669","market":"nz","top_or_hot":-1,"title":"Alnylam Commits Up to $2B to AI-Driven Therapeutic Innovation -- Company Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Alnylam's new strategic partnership with Inceptive Nucleics carries a potential value of up to $2 billion, with an upfront payment of $30 million in cash and equity. The deal pairs Inceptive's generative artificial intelligence models with Alnylam's research engine as part of the company's Alnylam 2030 strategy. Alnylam CEO Yvonne Greenstreet said the collaboration aims to accelerate the creation of transformative medicines with speed and sophistication not previously possible. The structure includes additional milestone payments tied to preclinical, regulatory, and commercial achievements. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n     This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2026 17:28 ET (21:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam Commits Up to $2B to AI-Driven Therapeutic Innovation -- Company Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam Commits Up to $2B to AI-Driven Therapeutic Innovation -- Company Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-04 05:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Alnylam's new strategic partnership with Inceptive Nucleics carries a potential value of up to $2 billion, with an upfront payment of $30 million in cash and equity. The deal pairs Inceptive's generative artificial intelligence models with Alnylam's research engine as part of the company's Alnylam 2030 strategy. Alnylam CEO Yvonne Greenstreet said the collaboration aims to accelerate the creation of transformative medicines with speed and sophistication not previously possible. The structure includes additional milestone payments tied to preclinical, regulatory, and commercial achievements. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n     This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2026 17:28 ET (21:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2640182669","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640182669","pubTimestamp":1780522080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Alnylam's new strategic partnership with Inceptive Nucleics carries a potential value of up to $2 billion, with an upfront payment of $30 million in cash and equity. The deal pairs Inceptive's generative artificial intelligence models with Alnylam's research engine as part of the company's Alnylam 2030 strategy. Alnylam CEO Yvonne Greenstreet said the collaboration aims to accelerate the creation of transformative medicines with speed and sophistication not previously possible. The structure includes additional milestone payments tied to preclinical, regulatory, and commercial achievements.This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4548":"巴美列捷福持仓","BK4139":"生物科技","AGIX":"通用人工智能 ETF-AGIX","ALNY":"阿尔尼拉姆制药公司","AIPO":"Defiance AI and Power Infrastructure ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC"},"translate_title":"Alnylam承诺投入高达20亿美元用于人工智能驱动的治疗创新——公司演讲","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIX":1.5,"ARTY":1.5,"AIPO":1.5,"CHAT":1.5,"ALNY":0.9},"content_text":"Alnylam's new strategic partnership with Inceptive Nucleics carries a potential value of up to $2 billion, with an upfront payment of $30 million in cash and equity. The deal pairs Inceptive's generative artificial intelligence models with Alnylam's research engine as part of the company's Alnylam 2030 strategy. Alnylam CEO Yvonne Greenstreet said the collaboration aims to accelerate the creation of transformative medicines with speed and sophistication not previously possible. The structure includes additional milestone payments tied to preclinical, regulatory, and commercial achievements. \n\n\n \n\n\n     This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 03, 2026 17:28 ET (21:28 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}